Press releases

First patient enrolled in Oncopeptides’ glioblastoma study

Oncopeptides submits Type II variation application to EMA for Pepaxti label expansion into third line treatment

First patient enrolled in Oncopeptides’ real-world evidence study MARINA in Germany

Oncopeptides to present clinical and translational data on Pepaxti at EHA 2026 in Stockholm

Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe

Bulletin from the Annual General Meeting in Oncopeptides

Study confirms use of Pepaxti in a broader population, with strong data in the 50% of RRMM patients that suffer from reduced kidney function

Oncopeptides receives formal approval from Norwegian authorities to initiate Window-of-Opportunity study in glioblastoma

COMy: New clinical and real-world evidence for Pepaxti demonstrating strong data and expanded positioning

Oncopeptides publishes Q1 report 2026

Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment

Invitation to presentation of the Q1 report 2026